Inductive Bio Nets $25 Million to Predict Better Drugs with AI

The newly secured funding will enable Inductive Bio to expand its AI model research and development, grow its data consortium, and deploy its technology industry-wide
Inductive Bio, a New York-based startup, has announced a $25 million Series A funding round aimed at transforming small molecule drug discovery through advanced artificial intelligence. The round was led by Obvious Ventures, with participation from prominent investors including Andreessen Horowitz (a16z) Bio + Health, Lux Capital, S32, Character, and Amino Collective. Notable angel investors such as Oren Etzioni, Jeff Hammerbacher, Malay Gandhi, and Jakob Uszkoreit also contributed to the funding. Addressing the Bottlenecks in Drug Discovery The pharmaceutical industry faces mounting challenges, including escalating costs, prolonged development timelines, and increasing competition. A critical hurdle in preclinical drug development is optimising a compound's ADMET properties: absorpt
Subscribe or log in to Continue Reading

Uncompromising innovation. Timeless influence. Your support powers the future of independent tech journalism.

Already have an account? Sign In.

📣 Want to advertise in AIM Media House? Book here >

Picture of Upasana Banerjee
Upasana Banerjee
Upasana is a Content Strategist with AIM Research. Prior to her role at AIM, she worked as a journalist and social media editor, and holds a strong interest for global politics and international relations. Reach out to her at: upasana.banerjee@analyticsindiamag.com
25 July 2025 | 583 Park Avenue, New York
The Biggest Exclusive Gathering of CDOs & AI Leaders In United States

Subscribe to our Newsletter: AIM Research’s most stimulating intellectual contributions on matters molding the future of AI and Data.